Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial

The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age <10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2·64, 95% CI 1·32, 5·31, p = 0·006 for OS). ALL R3 showed an improvement in outcome for CNS relapses treated with Mitoxantrone compared to Idarubicin; a potential benefit for matched donor transplant for those with very early and early isolated-CNS relapses. Trial Registration Controlled-Trials.com ISRCTN45724312

[1]  R. Meek,et al.  Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. , 2000, Medical and pediatric oncology.

[2]  A. O'marcaigh,et al.  Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies , 2001, Acta paediatrica.

[3]  R. Pieters,et al.  Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Medical and pediatric oncology.

[4]  M. Valsecchi,et al.  Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia , 2010, Leukemia.

[5]  A. Moorman,et al.  A population-based cytogenetic study of adults with acute lymphoblastic leukemia. , 2010, Blood.

[6]  L. Gibson,et al.  Cellular elements of the subarachnoid space promote ALL survival during chemotherapy. , 2011, Leukemia research.

[7]  A. Gibson,et al.  Short-term growth: rhythms, chaos, or noise? , 1994, Archives of disease in childhood.

[8]  K. Dietz,et al.  Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Willemze,et al.  Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40 , 2011, Leukemia.

[10]  J. Beijnen,et al.  Penetration of Idarubicin into Malignant Brain Tumor Tissue , 1999, Journal of Neuro-Oncology.

[11]  W. Bleyer,et al.  Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995 , 2000, Leukemia.

[12]  S. Richards,et al.  Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial , 2005, British journal of haematology.

[13]  S. Richards,et al.  Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997 , 2000, Leukemia.

[14]  M. Loh,et al.  Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study , 2008, Leukemia.

[15]  S. Mehta,et al.  Diminished Anticoagulant Effects of Warfarin with Concomitant Mercaptopurine Therapy , 2003, Pharmacotherapy.

[16]  T. Klingebiel,et al.  Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL , 2002, Leukemia.

[17]  M. Relling,et al.  Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia , 1998, Leukemia.

[18]  M. Schrappe,et al.  Intermediate Dose Methotrexate Is as Effective as High Dose Methotrexate in Preventing Isolated Testicular Relapse in Childhood Acute Lymphoblastic Leukemia , 1998, Journal of pediatric hematology/oncology.

[19]  Avis J. Thomas,et al.  Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  S. Schuster,et al.  Methotrexate stimulation of asparagine synthetase activity in rat liver. , 1982, Life sciences.

[21]  G. Henze,et al.  Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. , 2003, Blood.

[22]  M. Schrappe,et al.  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Ozisik,et al.  Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: results of two consecutive phase II clinical studies. , 1998, Cancer investigation.

[24]  C. Pui,et al.  An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Great,et al.  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial , 2010, The Lancet.

[26]  H. Sather,et al.  Long Term Results of the Children’s Cancer Group Studies for Childhood Acute Lymphoblastic Leukemia 1983–2002: a Children’s Oncology Group Report , 2009, Leukemia.

[27]  T. Taylor.  A group experience. , 1990, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[28]  R. Wade,et al.  Temporal changes in incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council Trials, 1985–2001 , 2009, Leukemia.

[29]  J. Harbott,et al.  Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 , 2010, Leukemia.

[30]  G. Burmester,et al.  Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. , 2000, The Journal of rheumatology.

[31]  T. Imamura,et al.  Allogeneic stem cell transplantation in children with acute lymphoblastic leukemia after isolated central nervous system relapse: our experiences and review of the literature , 2006, Bone Marrow Transplantation.

[32]  S. Feig,et al.  High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. , 1998, Medical and pediatric oncology.

[33]  C. Pui,et al.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications. , 2009, Seminars in oncology.

[34]  G. Chrousos,et al.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Love,et al.  Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial , 2005, British journal of haematology.

[36]  F. Khan,et al.  Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme , 2004, Bone Marrow Transplantation.

[37]  D. Campana,et al.  Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Crispin J. Miller,et al.  RAC2, AEP, and ICAM1 expression are associated with CNS disease in a mouse model of pre-B childhood acute lymphoblastic leukemia. , 2011, Blood.

[39]  J. Hancock,et al.  Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. , 1998, Blood.

[40]  G. Dini,et al.  Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia , 1998, Bone Marrow Transplantation.

[41]  P. Veys,et al.  Haploidentical related transplants and unrelated donor transplants with T cell addback. , 1998, Bone marrow transplantation.

[42]  B. Pollock,et al.  Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study . , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  C. Pui,et al.  Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children , 1996, The Lancet.

[44]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[45]  H. El-Solh,et al.  ENHANCED VINCRISTINE NEUROTOXICITY FROM DRUG INTERACTIONS: Case Report and Review of Literature , 2001, Pediatric hematology and oncology.

[46]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[47]  H. Dombret,et al.  Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Sarper,et al.  FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children. , 2000, Medical and pediatric oncology.

[49]  G. Dini,et al.  Bone marrow transplant indications for childhood leukemias: achieving a consensus. The EBMT Pediatric Diseases Working Party. , 1996, Bone marrow transplantation.

[50]  S. Richards,et al.  Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  H. Kanegane,et al.  Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia , 2010, Leukemia.

[52]  K. Greenlund,et al.  Use of weight-for-height indices in children to predict adult overweight: the Bogalusa Heart Study. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[53]  R. Wade,et al.  Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. , 2013, The Lancet. Oncology.

[54]  N. Dastugue,et al.  Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Richards,et al.  Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. , 2010, The Lancet. Oncology.

[56]  R. Willemze,et al.  High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40 , 2009 .

[57]  P. Steinherz,et al.  Survival after relapse in childhood acute lymphoblastic leukemia , 1998, Cancer.

[58]  R. Gelber,et al.  Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Schrappe,et al.  Pegylated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL‐BFM 95 protocols , 2000, British journal of haematology.

[60]  J. Lilleyman.  Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia. , 1998, Leukemia & lymphoma.

[61]  H. Kantarjian,et al.  Phase I study of liposomal daunorubicin in patients with acute leukemia , 1999, Investigational New Drugs.

[62]  E. Froňková,et al.  Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group. , 2007, Blood.

[63]  V. Koseoglu,et al.  Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide , 1999, Bone Marrow Transplantation.

[64]  S. Richards,et al.  Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute Lymphoblastic leukaemia, 1980–2001 , 2009, Leukemia.

[65]  Richards,et al.  The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study , 2000, British journal of haematology.

[66]  D. Platel,et al.  Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model. , 1999, Anti-cancer drugs.

[67]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[68]  W. Kamps,et al.  Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004 , 2010, Leukemia.

[69]  J. Downing,et al.  Improved prognosis for older adolescents with acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[71]  K. Schmiegelow,et al.  Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia , 2010, Leukemia.